Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 669


Whipworm Infection Promotes Bacterial Invasion, Intestinal Microbiota Imbalance, and Cellular Immunomodulation.

Schachter J, Alvarinho de Oliveira D, da Silva CM, de Barros Alencar ACM, Duarte M, da Silva MMP, Ignácio ACPR, Lopes-Torres EJ.

Infect Immun. 2020 Feb 20;88(3). pii: e00642-19. doi: 10.1128/IAI.00642-19. Print 2020 Feb 20.


The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies.

Zippel D, Yalon T, Nevo Y, Markel G, Asher N, Schachter J, Goitein D, Segal TA, Nissan A, Hazzan D.

Am J Surg. 2019 Nov 26. pii: S0002-9610(19)31547-8. doi: 10.1016/j.amjsurg.2019.11.033. [Epub ahead of print]


Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy.

Yunger S, Bar El A, Zeltzer LA, Fridman E, Raviv G, Laufer M, Schachter J, Markel G, Itzhaki O, Besser MJ.

Oncoimmunology. 2019 Oct 11;8(12):e1672494. doi: 10.1080/2162402X.2019.1672494. eCollection 2019.


Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.

Zippel D, Friedman-Eldar O, Rayman S, Hazzan D, Nissan A, Schtrechman G, Markel G, Schachter J, Itzhaki O, Besser MJ.

Anticancer Res. 2019 Sep;39(9):4995-5001. doi: 10.21873/anticanres.13689.


TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.

Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R.

Cancer Immunol Immunother. 2019 Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9.


Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.

Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E, Shenoy A, Ayasun R, Knafo N, Xu S, Anafi L, Yanovich-Arad G, Barnabas GD, Ashkenazi S, Besser MJ, Schachter J, Bosenberg M, Shadel GS, Barshack I, Kaech SM, Markel G, Geiger T.

Cell. 2019 Sep 19;179(1):236-250.e18. doi: 10.1016/j.cell.2019.08.012. Epub 2019 Sep 5.


Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.

Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ.

J Med Chem. 2019 Nov 27;62(22):10062-10097. doi: 10.1021/acs.jmedchem.9b01090. Epub 2019 Sep 29.


Mycoplasma genitalium, Chlamydia trachomatis, and Neisseria gonorrhoeae Detected With Aptima Assays Performed on Self-Obtained Vaginal Swabs and Urine Collected at Home and in a Clinic.

Chernesky M, Jang D, Martin I, Arias M, Shah A, Smieja M, Ratnam S, Getman D, Schachter J.

Sex Transm Dis. 2019 Sep;46(9):e87-e89. doi: 10.1097/OLQ.0000000000001004.


Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.


Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.


Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.


Alternate Nucleic Acid Targets Can Be Used To Create a Composite Standard To Evaluate Clinical Performance of Nucleic Acid Amplification Tests.

Schachter J, Chernesky M.

J Clin Microbiol. 2019 Jul 26;57(8). pii: e00661-19. doi: 10.1128/JCM.00661-19. Print 2019 Aug.


A review of protection against exposome factors impacting facial skin barrier function with 89% mineralizing thermal water.

Salsberg J, Andriessen A, Abdulla S, Ahluwalia R, Beecker J, Sander M, Schachter J.

J Cosmet Dermatol. 2019 Jun;18(3):815-820. doi: 10.1111/jocd.12927. Epub 2019 Apr 9. Review.


Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.


Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.


Early and late hematologic toxicity following CD19 CAR-T cells.

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E.

Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.


Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.

Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.

Oncologist. 2019 May;24(5):640-647. doi: 10.1634/theoncologist.2018-0352. Epub 2019 Feb 18.


Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.

Ben-Betzalel G, Steinberg-Silman Y, Stoff R, Asher N, Shapira-Frommer R, Schachter J, Markel G.

Eur J Cancer. 2019 Feb;108:61-68. doi: 10.1016/j.ejca.2018.12.012. Epub 2019 Jan 14.


ATPe Dynamics in Protozoan Parasites. Adapt or Perish.

Lauri N, Bazzi Z, Alvarez CL, Leal Denis MF, Schachter J, Herlax V, Ostuni MA, Schwarzbaum PJ.

Genes (Basel). 2018 Dec 27;10(1). pii: E16. doi: 10.3390/genes10010016. Review.


An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.


Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.

J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print]


Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.

Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G.

Cancer Immunol Res. 2018 Dec;6(12):1453-1458. doi: 10.1158/2326-6066.CIR-17-0659. Epub 2018 Oct 1.


Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M.

Br J Cancer. 2018 Sep;119(6):670-674. doi: 10.1038/s41416-018-0207-6. Epub 2018 Sep 11.


Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.

Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, Meir A, Kubi A, Levy M, Zikich D, Zeltzer LA, Brezinger K, Schachter J, Nagler A, Besser MJ, Toren A.

Am J Hematol. 2018 Dec;93(12):1485-1492. doi: 10.1002/ajh.25274. Epub 2018 Sep 26.


FibroSURE and elastography poorly predict the severity of liver fibrosis in Fontan-associated liver disease.

Schachter JL, Patel M, Horton SR, Mike Devane A, Ewing A, Abrams GA.

Congenit Heart Dis. 2018 Sep;13(5):764-770. doi: 10.1111/chd.12650. Epub 2018 Aug 12.


Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.

Eur J Cancer. 2018 Sep;101:229-235. doi: 10.1016/j.ejca.2018.06.030. Epub 2018 Aug 7.


Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.

Schultz MK Jr, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala HA.

Neurobiol Dis. 2018 Oct;118:161-176. doi: 10.1016/j.nbd.2018.07.003. Epub 2018 Jul 7.


ADAR1-mediated regulation of melanoma invasion.

Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.

Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.


Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.

Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ.

Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230. doi: 10.1007/s00262-018-2174-4. Epub 2018 May 29.


Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.

Wang X, Smith K, Pearson M, Hughes A, Cosden ML, Marcus J, Hess JF, Savage MJ, Rosahl T, Smith SM, Schachter JB, Uslaner JM.

PLoS One. 2018 Apr 6;13(4):e0195486. doi: 10.1371/journal.pone.0195486. eCollection 2018.


Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G.

Neoplasia. 2018 Apr;20(4):401-409. doi: 10.1016/j.neo.2018.01.012. Epub 2018 Mar 17.


Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.


Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.

Autoimmun Rev. 2018 Mar;17(3):284-289. doi: 10.1016/j.autrev.2018.01.003. Epub 2018 Jan 16.


Plasmodium falciparum invasion and intraerythrocytic development are impaired by 2', 3'-dialdehyde adenosine.

Silva LS, Prado GC, Quintana PG, Heise N, Miranda KR, Torres EJL, Persechini PM, de Sá Pinheiro AA, Schachter J.

Microbes Infect. 2018 Mar;20(3):205-211. doi: 10.1016/j.micinf.2017.11.015. Epub 2017 Dec 15.


Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma.

Galore-Haskel G, Baruch EN, Berg AL, Barshack I, Zilinsky I, Avivi C, Besser MJ, Schachter J, Markel G.

Oncotarget. 2017 Sep 14;8(59):99580-99586. doi: 10.18632/oncotarget.20884. eCollection 2017 Nov 21.


Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.


Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.

Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Markel G, Schachter J, Besser MJ.

Front Immunol. 2017 Oct 10;8:1211. doi: 10.3389/fimmu.2017.01211. eCollection 2017.


POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.

Pimenta-Dos-Reis G, Torres EJL, Quintana PG, Vidal LO, Dos Santos BAF, Lin CS, Heise N, Persechini PM, Schachter J.

Purinergic Signal. 2017 Dec;13(4):611-627. doi: 10.1007/s11302-017-9588-x. Epub 2017 Oct 11.


Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.


Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.


Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM.

N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.


Effects of obesity on depression: A role for inflammation and the gut microbiota.

Schachter J, Martel J, Lin CS, Chang CJ, Wu TR, Lu CC, Ko YF, Lai HC, Ojcius DM, Young JD.

Brain Behav Immun. 2018 Mar;69:1-8. doi: 10.1016/j.bbi.2017.08.026. Epub 2017 Sep 6. Review.


Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.


Perioperative BRAF inhibitors in locally advanced stage III melanoma.

Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S.

J Surg Oncol. 2017 Dec;116(7):856-861. doi: 10.1002/jso.24744. Epub 2017 Jun 26.


Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.


Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion.

Hadfield J, Harris SR, Seth-Smith HMB, Parmar S, Andersson P, Giffard PM, Schachter J, Moncada J, Ellison L, Vaulet MLG, Fermepin MR, Radebe F, Mendoza S, Ouburg S, Morré SA, Sachse K, Puolakkainen M, Korhonen SJ, Sonnex C, Wiggins R, Jalal H, Brunelli T, Casprini P, Pitt R, Ison C, Savicheva A, Shipitsyna E, Hadad R, Kari L, Burton MJ, Mabey D, Solomon AW, Lewis D, Marsh P, Unemo M, Clarke IN, Parkhill J, Thomson NR.

Genome Res. 2017 Jul;27(7):1220-1229. doi: 10.1101/gr.212647.116. Epub 2017 Jun 6.


Adoptive T cell therapy: An overview of obstacles and opportunities.

Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G.

Cancer. 2017 Jun 1;123(S11):2154-2162. doi: 10.1002/cncr.30491. Review.


The Art of Feedback in Medical Practice.

Schachter J.

J Obstet Gynaecol Can. 2017 Aug;39(8):682-683. doi: 10.1016/j.jogc.2017.03.088. Epub 2017 May 11. No abstract available.


Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.


Adoptive Cell Therapy for Metastatic Melanoma.

Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ.

Cancer J. 2017 Jan/Feb;23(1):48-53. doi: 10.1097/PPO.0000000000000240. Review.


Supplemental Content

Loading ...
Support Center